Axonal damage and its significance for the concept of neurodegeneration in multiple sclerosis;Die Bedeutung axonaler Pathologie für das Konzept der Neurodegeneration bei der Multiplen Sklerose

Fortschritte der Neurologie Psychiatrie

Volumn 79, Issue 3, 2011, Pages 161-170

  Recks, M S ^a   Bader, J ^a   Kaiser, C C ^a   Schroeter, M ^a   Fink, G R ^a   Addicks, K ^a   Kuerten, S ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

axonal damage; demyelination; EAE; inflammation; MS

Indexed keywords

ARTICLE; AXONAL DAMAGE; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE DEGENERATION; PATHOPHYSIOLOGY;

AXONAL TRANSPORT; AXONS; DEMYELINATING DISEASES; HUMANS; INFLAMMATION; MITOCHONDRIA; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952318144     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0029-1246014     Document Type: Article

References (61)

1. Kornek B, Lassmann H. Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 1999 9 651-656 (Pubitemid 29470958)
2. Trapp B D., Peterson J, Ransohoff R M. et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998 338 278-285 (Pubitemid 28065253)
3. Allen I V., McQuaid S, Mirakhur M et al. Pathological abnormalities in the normal-appearing white matter in multiple sclerosis. Neurol Sci 2001 22 141-144 (Pubitemid 33771280)
4. Bitsch A, Schuchardt J, Bunkowski S et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000 123 1174-1183 (Pubitemid 30312109)
5. Goverman J, Brabb T. Rodent models of experimental allergic encephalomyelitis applied to the study of multiple sclerosis. Lab Anim Sci 1996 46 482-492
6. Kuerten S, Angelov D N. Comparing the CNS morphology and immunobiology of different EAE models in C 57BL/ 6 mice - a step towards understanding the complexity of multiple sclerosis. Ann Anat 2008 190 1-15
7. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005 23 683-747 (Pubitemid 40563183)
8. Wucherpfennig K W. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 2001 108 1097-1104 (Pubitemid 32995366)
9. Lehmann P V., Forsthuber T, Miller A et al. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992 358 155-157
10. Hickey W F. Basic principles of immunological surveillance of the normal central nervous system. Glia 2001 36 118-124 (Pubitemid 33055900)
11. Plumb J, McQuaid S, Mirakhur M et al. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 2002 12 154-169 (Pubitemid 34259917)
12. Yednock T A., Cannon C, Fritz L C. et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992 356 63-66
13. Kent S J., Karlik S J., Cannon C et al. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995 58 1-10
14. Rudick R A., Stuart W H., Calabresi P A. et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006 354 911-923
15. Reboldi A, Coisne C, Baumjohann D et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009 10 514-523
16. Menge T, Lalive P H., Büdingen H C. et al. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol 2005 116 453-459 (Pubitemid 41096558)
17. Ehling R von, Lutterotti A, Wanschitz J et al. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult Scler 2004 10 601-606 (Pubitemid 39585235)
18. Silber E, Semra Y K., Gregson N A. et al. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002 58 1372-1381 (Pubitemid 34507164)
19. Mathey E K., Derfuss T, Storch M K. et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007 204 2363-2372 (Pubitemid 47529322)
20. Aloisi F, Ria F, Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 2000 21 141-147
21. Neumann H, Medana I M., Bauer J et al. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002 25 313-319 (Pubitemid 34667013)
22. Lucchinetti C, Brück W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000 47 707-717 (Pubitemid 30390191)
23. Niepel G G., Constantinescu C S. Aetiology and pathogenesis of Multiple sclerosis. Hosp Pharm 2003 10 13-16 (Pubitemid 36090930)
24. Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001 7 115-121 (Pubitemid 32201673)
25. Coleman M P., Perry V H. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 2002 25 532-537 (Pubitemid 35246324)
26. Perry V H., Anthony D C. Axon damage and repair in multiple sclerosis. Philos Trans R Soc Lond B Biol Sci 1999 354 1641-1647 (Pubitemid 29534431)
27. De Stefano N, Matthews P M., Fu L et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998 121 1469-1477 (Pubitemid 28349900)
28. Ferguson B, Matyszak M K., Esiri M M. et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997 120 393-399 (Pubitemid 27153632)
29. Batoulis H, Addicks K, Kuerten S. Emerging concepts in autoimmune encephalomyelitis beyond the CD 4 /T(H)1 paradigm. Ann Anat 2010 192 179-193
30. Rivera-Quiñones C, McGavern D, Schmelzer J D. et al. Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat Med 1998 4 187-193 (Pubitemid 28137373)
31. Howe C L., Adelson J D., Rodriguez M. Absence of perforin expression confers axonal protection despite demyelination. Neurobiol Dis 2007 25 354-359 (Pubitemid 46124015)
32. Medana I, Martinic M A., Wekerle H et al. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 2001 159 809-815 (Pubitemid 32847171)
33. Neumann H, Schweigreiter R, Yamashita T et al. Tumor necrosis factor inhibits neurite outgrowth and branching of hippocampal neurons by a rho-dependent mechanism. J Neurosci 2002 22 854-862 (Pubitemid 34141766)
34. Piani D, Fontana A. Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons. J Immunol 1994 152 3578-3585
35. Pitt D, Werner P, Raine C S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000 6 67-70 (Pubitemid 30048528)
36. Bö L, Dawson T M., Wesselingh S et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994 36 778-786 (Pubitemid 24337639)
37. Redford E J., Kapoor R, Smith K J. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997 120 2149-2157 (Pubitemid 28014591)
38. Mead R J., Singhrao S K., Neal J W. et al. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 2002 168 458-465 (Pubitemid 34014149)
39. Singhrao S K., Neal J W., Rushmere N K. et al. Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol 2000 157 905-918 (Pubitemid 32109383)
40. Mao P, Reddy P H. Is multiple sclerosis a mitochondrial disease? Biochim Biophys Acta 2010 1802 66-79
41. Schon E A., Manfredi G. Neuronal degeneration and mitochondrial dysfunction. J Clin Invest 2003 111 303-312 (Pubitemid 36182203)
42. Dautry C, Vaufrey F, Brouillet E et al. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab 2000 20 789-799 (Pubitemid 30317053)
43. Narayana P A., Doyle T J., Lai D et al. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998 43 56-71 (Pubitemid 28124649)
44. De Stefano N, Narayanan S, Francis S J. et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 2002 59 1565-1571
45. Adams J H., Graham D I., Gennarelli T A. et al. Diffuse axonal injury in non-missile head injury. J Neurol Neurosurg Psychiatry 1991 54 481-483
46. Kamal A, Stokin G B., Yang Z et al. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 2000 28 449-459
47. Kamal A, Almenar-Queralt A, LeBlanc J F. et al. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 2001 414 643-648 (Pubitemid 33151260)
48. Müller U, Kins S. APP on the move. Trends Mol Med 2002 8 152-155 (Pubitemid 34297084)
49. Lunn M P., Crawford T O., Hughes R A. et al. Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing. Brain 2002 125 904-911 (Pubitemid 34279784)
50. Edgar J M., McLaughlin M, Werner H B. et al. Early ultrastructural defects of axons and axon-glia junctions in mice lacking expression of Cnp1. Glia 2009 57 1815-1824
51. Lappe-Siefke C, Goebbels S, Gravel M et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 2003 33 366-374 (Pubitemid 36278853)
52. Morfini G A., Burns M, Binder L I. et al. Axonal transport defects in neurodegenerative diseases. J Neurosci 2009 29 12 776-12 786
53. Wilkins A, Majed H, Layfield R et al. Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. Neurosci 2003 23 4967-4974 (Pubitemid 36793223)
54. Garbern J Y., Yool D A., Moore G J. et al. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 2002 125 551-561 (Pubitemid 34194410)
55. Chang A, Tourtellotte W W., Rudick R et al. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002 346 165-173 (Pubitemid 34438882)
56. De Stefano N, Matthews P M., Filippi M et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003 60 1157-1162 (Pubitemid 36418778)
57. Narayanan S, De Stefano N, Francis G S. et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001 248 979-986 (Pubitemid 36124725)
58. Khan O, Shen Y, Caon C et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2005 11 646-651 (Pubitemid 41685134)
59. Paolillo A, Coles A J., Molyneux P D. et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1 H. Neurology 1999 53 751-757 (Pubitemid 29448295)
60. Groom A J., Smith T, Turski L. Multiple sclerosis and glutamate. Ann N Y Acad Sci 2003 993 229-275 (Pubitemid 36808454)
61. Kalkers N F., Barkhof F, Bergers E et al. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 2002 8 532-533 (Pubitemid 35396406)